When ministers stood behind the medicines agreement struck with Washington last December, the language was the language of statecraft. Tariffs averted. Investment secured. British drugs flowing to American shelves unimpeded. What went largely unmentioned was who inside the government would actually write the cheque. That answer arrived quietly in February, when the science minister confirmed the costs would sit with the Department of Health and Social Care rather than the Treasury. Read alongside analysis now published in the British Medical Journal, the arithmetic is stark. Up to £44.7bn diverted from NHS services by 2036, and as many as 229,000 avoidable deaths in England as a result of the care those funds would otherwise have paid for.

This is not simply a story about trade policy or pharmaceutical pricing. It is a story about how commitments made in the name of diplomatic pragmatism land, eventually, on hospital finance directors and the patients on their waiting lists. The deal commits England to nearly doubling the share of GDP it spends on innovative medicines over the coming decade, a shift agreed under pressure from an American administration threatening tariffs of up to 100% on pharmaceutical imports. Framed as a defensive measure for British life sciences exporters, it functions, in practice, as an open-ended liability sitting inside an NHS budget that has no comparable slack to absorb it.

For NHS leaders already managing a service under acute financial strain, the implications are immediate rather than theoretical. Every additional pound spent on higher-priced medicines is a pound unavailable for community services, prevention programmes or the workforce expansion that successive governments have promised. The unification of integrated care boards and Sir Jim Mackey's contract responsibility campaign were both based on taking efficiency out of a system that was already overburdened. A multibillion-pound annual liability layered on top of that effort does not merely complicate the maths. It threatens to hollow out the very reforms designed to make the NHS sustainable.

The political timing sharpens the stakes further. As Andy Burnham assembles a government still finding its footing on health policy, and as the search for a health secretary continues amid uncertainty over the department's direction, this is precisely the kind of inherited liability that defines an incoming administration's credibility. Burnham has signalled instincts toward devolution and local control, but devolved structures cannot absorb a centrally negotiated trade commitment whose costs were fixed before he took office. The government's insistence that the deal will cost only £1bn through 2028-29, with no public estimate offered beyond that point, looks less like reassurance than deferral. Someone will eventually have to explain the gap between that figure and the BMJ's projection, and it is unlikely to be the ministers who signed the original agreement.

Anyone who has observed the NHS's recent record of choices taken without sufficient parliamentary supervision should be concerned about this quieter debate over accountability and scrutiny. The medicines deal was not subjected to a published impact assessment before being agreed. That pattern, of consequential health policy shaped by negotiations conducted largely out of view, echoes debates that have already damaged public confidence in NHS governance, from the Federated Data Platform controversy to the abolition of NHS England itself. Each case reinforces the sense that decisions with profound implications for patient care are being made at a distance from the institutions meant to hold them to account.

None of this means the underlying goal, protecting British pharmaceutical exports and expanding patient access to newer treatments, was inherently wrong. However, this kind of policy cannot be evaluated just on the basis of the trade rationale that led to its creation. It has to be judged by what it costs the system asked to fund it. If the BMJ's projections hold even approximately, the NHS has been handed a bill it did not choose and cannot easily pay, and the reckoning will fall to whichever health secretary inherits it.